Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Hepatol. Mar 27, 2013; 5(3): 120-126
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.120
Table 1 Characteristics of the studies included in the systematic analysis
Ref.Study designNo. of patientsAge (yr)WeightHCV genotypeBaseline treatment historyChild-Pugh classTreatment
Syed et al[12]Retrospective cohort study10452 ± 7.682 ± 15 kg (mean weight)1, 2, 3Naive and previously treatedAPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1-1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Butt et al[13]Prospective cohort study6646.2 ± 10.122.3 ± 3.1 kg/m² (mean BMI)3Naive and previously treatedA, BPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Giannini et al[14]Retrospective cohort study8556 ± 9Not specified1, 2, 3, 4Naive and previously treatedA, BPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/ d)
Helbling et al[15]Randomized controlled trial (standard doses vs low doses)6447 (median age)74 kg (median weight)1, 2, 3, 4NaiveAPegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/ d)
Iacobellis et al[16]Prospective cohort study94Not specifiedNot specified1, 2, 3, 4NaiveBPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Roffi et al[17]Randomized controlled trial (pegylated interferon vs IFN standard)5756 (median age)75 kg (median weight)1, 2, 3NaiveAPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800-1200 mg/d)
Sood et al[18]Retrospective cohort study2848.3 ± 773.9 ± 11.2 kg (mean weight)3 (25/28 patients) and not specified for the other patientsNaiveA, BPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Tekin et al[19]Cohort study2054.2 ± 5.9Not specified1Not specifiedA, BPegylated interferon alpha 2a (135 μg/wk)
Ribavirin (1000-1200 mg/d)
Moreno Planas et al[20]Cohort study1252 ± 8Not specified1, 3Naive and previously treatedA, BPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (10.6 mg/kg per day)
Di Marco et al[21]Randomized controlled trial (pegylated interferon alpha 2B + ribavirin vs pegylated interferon alpha 2b)5257 ± 6.671 ± 10.1 kg (mean weight)1, 2, 3, 4Naive and previously treatedA, BPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800 mg/d)
Höroldt et al[22]Retrospective cohort study61Not specifiedNot specified1, 2, 3NaiveA, BPegylated interferon alpha 2a or alpha 2b + ribavirin
Bruno et al[23]Randomized study106Not specifiedNot specified1, 2, 3, 4NaiveAPegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Floreani et al[24]Prospective cohort study8755.7 ± 9.125.3 ± 3.1 kg/m² (mean BMI)1, 2, 3NaiveAPegylated interferon alpha 2b (80-100 μg/wk)
Ribavirin (1000-1200 mg/d)
Annicchiarico et al[25]Prospective cohort study1551.5Not specified1, 2, 3Naive and previously treatedB, CPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Aghemo et al[26]Prospective cohort study10657 ± 9.372.5 ± 11.8 kg (mean weight)1, 2, 3, 4NaiveAPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (≥ 10.6 mg/kg per day)
Kim et al[27]Cohort study8656.4 ± 9.6Not specified1 and non-1Not specifiedAPegylated interferon alpha 2b (1.5 μg/kg per week)
or Pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Reiberger et al[28]Prospective cohort study9051 ± 826.6 ± 5 kg/m² (mean BMI)1, 2, 3, 4Not specifiedAPegylated interferon alpha 2b (1.5 μg/kg per week)
or pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
HCV: Hepatitis C virus; BMI: Body mass index; IFN: Interferon.